Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Serratus Posterior Superior Intercostal Planblok versus Intratekal Morfin i VATs

1. oktober 2026 opdateret af: Cengiz KAYA, Ondokuz Mayıs University

Sammenligning af effekterne af Serratus Posterior Superior Intercostal Plane Blok og Intrathekal Morfin på postoperativ akut smerte hos patienter, der gennemgår videoassisteret torakoskopisk kirurgi

This study aims to compare the analgesic effects of the serratus posterior superior intercostal plane block and intrathecal morphine in patients undergoing video-assisted thoracoscopic surgery.

This is a prospective, randomized, controlled, single-center clinical trial including adult patients undergoing elective thoracoscopic surgery. Participants will be randomly assigned to receive either a serratus posterior superior intercostal plane block or intrathecal morphine before general anesthesia.

The primary outcome is cumulative opioid consumption during the first 24 postoperative hours, expressed as intravenous morphine milligram equivalents. Secondary outcomes include pain scores, time to first analgesic request, quality of recovery, and postoperative complications.

The study aims to determine whether these two techniques differ in their effectiveness for postoperative pain management.

Studieoversigt

Detaljeret beskrivelse

This study is a prospective, randomized, controlled, single-blinded, parallel-group clinical trial designed to compare the analgesic efficacy of serratus posterior superior intercostal plane block and intrathecal morphine in patients undergoing video-assisted thoracoscopic surgery.

Eligible patients aged 18-75 years with American Society of Anesthesiologists physical status I-III scheduled for elective thoracoscopic procedures (wedge resection, segmentectomy, or lobectomy) will be included. Patients will be randomized in a 1:1 ratio using a computer-generated sequence with block randomization.

Participants in the serratus posterior superior intercostal plane block group will receive an ultrasound-guided regional block prior to the induction of general anesthesia. Participants in the intrathecal morphine group will receive an intrathecal morphine injection before general anesthesia. All patients will receive standardized general anesthesia and postoperative patient-controlled analgesia.

The primary outcome is cumulative opioid consumption within the first 24 postoperative hours, expressed as intravenous morphine milligram equivalents.

Secondary outcomes include opioid consumption at 12 hours, numeric rating scale pain scores at rest and during activity, time to first analgesic request, quality of recovery scores, postoperative nausea and vomiting, sedation levels, pruritus, respiratory depression, and postoperative complications up to 30 days.

This study aims to evaluate the relative effectiveness of these two analgesic techniques and to improve postoperative pain management strategies in thoracic surgery.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

60

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Samsun
      • Atakent, Samsun, Tyrkiet (Türkiye), 55270
        • Ondokuz Mayis University

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 75 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Age between 18 and 75 years
  • American Society of Anesthesiologists physical status I to III
  • Scheduled for elective video-assisted thoracoscopic surgery, including wedge resection, segmentectomy, or lobectomy

Exclusion Criteria:

  • Refusal to participate
  • Pregnancy
  • Morbid obesity (body mass index greater than 40 kg per square meter)
  • Allergy to study medications
  • Neuropsychiatric disorders, cognitive impairment, or inability to communicate
  • History of substance abuse
  • Active systemic infection or infection at the planned injection site
  • Severe cardiac, respiratory, hepatic, renal, or endocrine disease.
  • Chronic pain syndrome or ongoing chronic pain treatment
  • Emergency surgery or previous ipsilateral VATS or thoracotomy
  • Preoperative opioid use: ≥15 mg oral morphine equivalents/day for ≥30 days within the previous 3 months.
  • Anticipated need for postoperative mechanical ventilation.
  • Contraindications to neuraxial or peripheral regional anesthesia, including anticoagulant therapy, coagulopathy, infection, or relevant anatomical abnormalities.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Intrathecal Morphine

Participants receive intrathecal morphine before induction of general anesthesia. Preservative-free morphine at 5 µg/kg based on ideal body weight is diluted with 0.9% saline to a total volume of 3 mL and administered intrathecally. All patients subsequently undergo standardized general anesthesia and receive postoperative patient-controlled analgesia with intravenous morphine.

Preservative-free morphine at 5 µg/kg based on ideal body weight is diluted with 0.9% saline to a total volume of 3 mL and administered intrathecally before induction of general anesthesia.

Eksperimentel: Serratus Posterior Superior Intercostal Plane Block

Participants receive an ultrasound-guided serratus posterior superior intercostal plane block before induction of general anesthesia. A total of 30 milliliters of 0.25 percent bupivacaine with epinephrine is administered into the interfascial plane between the serratus posterior superior muscle and intercostal muscles. All patients subsequently undergo standardized general anesthesia and receive postoperative patient-controlled analgesia with intravenous morphine.

Ultrasound-guided serratus posterior superior intercostal plane block is performed before induction of general anesthesia using 30 milliliters of 0.25 percent bupivacaine with epinephrine injected into the interfascial plane between the serratus posterior superior muscle and intercostal muscles.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Cumulative IV-MME during the first 24 hours after postoperative admission following extubation
Tidsramme: 24 hours

Total opioid consumption during the first 24 postoperative hours is expressed as intravenous morphine milligram equivalents, including patient-controlled analgesia and rescue analgesia.

24 hours

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Cumulative IV-MME during the first 12 hours after postoperative admission following extubation
Tidsramme: 12 hours

Total opioid consumption during the first 12 postoperative hours expressed as intravenous morphine milligram equivalents

12 hours
Postoperative pain scores
Tidsramme: 0, 3, 6, 12, 18, and 24 hours postoperatively

Pain intensity assessed using the 11-point Numeric Rating Scale (NRS; 0-10), where higher scores indicate greater pain intensity, with 0 representing no pain and 10 representing the worst imaginable pain, measured at rest and during activity.

0, 3, 6, 12, 18, and 24 hours postoperatively
Time to first patient-controlled analgesia demand
Tidsramme: 24 hours

Time from postoperative admission to the first PCA morphine demand.

24 hours
Quality of recovery score
Tidsramme: Preoperative baseline, 24 hours postoperatively, and at discharge

Quality of recovery assessed using the 15-item Quality of Recovery questionnaire (QoR-15; total score range 0-150), a validated patient-reported outcome measure where higher scores indicate better postoperative recovery.

Preoperative baseline, 24 hours postoperatively, and at discharge
Postoperative nausea and vomiting
Tidsramme: 0, 3, 6, 12, 18, and 24 hours postoperatively

Postoperative nausea and vomiting (PONV) will be assessed using a 4-point ordinal scale (0-3), where 0 indicates no nausea or vomiting, 1 indicates nausea without vomiting, 2 indicates a single episode of vomiting, and 3 indicates multiple episodes of vomiting; higher scores indicate worse symptoms. Scores >1 will be treated with ondansetron 4 mg IV; persistent symptoms will be treated with intravenous metoclopramide.

0, 3, 6, 12, 18, and 24 hours postoperatively
Sedation level
Tidsramme: 0, 3, 6, 12, 18, and 24 hours postoperatively

Sedation level assessed using the Ramsay Sedation Scale (RSS; 1-6), a validated ordinal scale where higher scores indicate deeper sedation, with 1 representing anxiety/agitation and 6 representing no response to stimuli.

0, 3, 6, 12, 18, and 24 hours postoperatively
Respiratory depression
Tidsramme: 24 hours

Incidence of respiratory depression defined as oxygen saturation below 90 percent or respiratory rate below 8 breaths per minute

24 hours
Pruritus
Tidsramme: 0, 3, 6, 12, 18, and 24 hours postoperatively

Incidence and severity of postoperative pruritus assessed using a 4-point ordinal scale (0-3), where 0 = no pruritus, 1 = mild pruritus (itching without scratching), 2 = moderate pruritus (itching with scratching), and 3 = severe pruritus requiring treatment; higher scores indicate worse symptoms.

0, 3, 6, 12, 18, and 24 hours postoperatively
Block-related complications
Tidsramme: Up to 30 days postoperatively

Incidence of post-dural puncture headache, paresthesia, hematoma, and local anesthetic systemic toxicity associated with the study interventions.

Up to 30 days postoperatively
Postoperative complications
Tidsramme: 30 days

Postoperative complications assessed using the Clavien-Dindo classification, where higher grades indicate more severe complications.

30 days
Remifentanil consumption
Tidsramme: Intraoperative period (from induction to end of surgery), up to 4 hours

Total intraoperative remifentanil consumption administered during surgery, measured in micrograms (µg).

Intraoperative period (from induction to end of surgery), up to 4 hours
Rescue analgesia requirement
Tidsramme: 24 hours

Incidence of patients requiring additional analgesia beyond patient-controlled analgesia

24 hours
Incidence of postoperative nausea and/or vomiting
Tidsramme: 24 hours postoperatively

Incidence of postoperative nausea and vomiting (PONV), defined as the occurrence of at least one episode of nausea and/or vomiting within the first 24 hours postoperatively (yes/no). Patients experiencing at least one episode will be classified as having PONV.

24 hours postoperatively
Propofol consumption
Tidsramme: Intraoperative period (from induction to end of surgery), up to 4 hours

Total intraoperative propofol consumption administered during surgery, measured in milligrams (mg).

Intraoperative period (from induction to end of surgery), up to 4 hours
Area under the numeric rating scale-time curve
Tidsramme: 0 to 24 hours postoperatively

The area under the numeric rating scale-time curve from 0 to 24 postoperative hours will be calculated separately for pain at rest and during activity using pain scores measured at 0, 3, 6, 12, 18, and 24 hours and the trapezoidal rule. Higher values indicate a greater cumulative pain burden.

0 to 24 hours postoperatively
Comprehensive Complication Index
Tidsramme: Up to 30 days postoperatively

Overall postoperative morbidity will be quantified using the Comprehensive Complication Index, which integrates all postoperative complications graded according to the Clavien-Dindo classification into a continuous score ranging from 0 to 100. Higher scores indicate greater overall morbidity.

Up to 30 days postoperatively

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

15. april 2026

Primær færdiggørelse (Faktiske)

15. august 2026

Studieafslutning (Faktiske)

15. september 2026

Datoer for studieregistrering

Først indsendt

9. april 2026

Først indsendt, der opfyldte QC-kriterier

16. april 2026

Først opslået (Faktiske)

20. april 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

5. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

1. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner